China Patient Derived Xenografts/PDX Models Market (2025-2030)
The China Patient Derived Xenografts/PDX Models Market was valued at $19.9 Million in 2025 and projected to reach to $34.2 Million by 2030, representing a compound annual growth rate of 11.4%. China's PDX models market is poised for sustained growth as the nation prioritizes precision medicine and oncology research within its healthcare modernization agenda.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
China Patient Derived Xenografts/PDX Models Market Trends and Insights
- This growth trajectory reflects China's increasing investment in precision oncology research and personalized medicine initiatives.
- China is strengthening its position as a key hub for preclinical drug development, driven by rising pharmaceutical R&D spending and government support for biotechnology innovation. The PDX models market in China is propelled by growing adoption among academic institutions, contract research organizations, and biopharmaceutical companies seeking advanced tumor modeling solutions.
- China's expanding cancer research infrastructure and collaborations with international pharmaceutical firms are accelerating demand for patient-derived xenograft platforms.
- Between 2025 and 2030, China is expected to capture significant market share within the Asia Pacific region, supported by regulatory reforms and increased focus on translational medicine..
Key Market Statistics
- CAGR (2025-2030) 11.4% CAGR
- Market Size, 2025 ~USD 19.9 Million
- Forecast, 2030 ~USD 34.2 Million
- Country China
China Patient Derived Xenografts/PDX Models Market Overview
Rapid Market Expansion :
China's PDX models market is growing at 11.4% CAGR, expanding from $19.9 million in 2025 to $34.2 million by 2030, driven by increased government funding for precision oncology research.
Precision Oncology Leadership :
China is establishing itself as a regional leader in personalized medicine, with major pharmaceutical companies and research institutions investing heavily in PDX model development for cancer drug discovery.
Preclinical Drug Development Hub :
The country is becoming a critical hub for preclinical testing, attracting international biotech firms seeking cost-effective, high-quality PDX services and reducing overall drug development timelines.
Government Support & Infrastructure :
Chinese government initiatives promoting biotechnology innovation and increased healthcare R&D budgets are accelerating adoption of PDX models across academic institutions and contract research organizations.
China Patient Derived Xenografts/PDX Models Market Dynamics
- The convergence of government support, rising pharmaceutical R&D investments, and growing collaboration between domestic and international biotech companies is creating favorable conditions for market expansion.
- Chinese CROs and academic centers are rapidly building PDX capabilities to meet both domestic and international demand. By 2030, China is expected to capture significant market share in Asia-Pacific's PDX sector, driven by cost advantages, expanding research infrastructure, and increasing clinical adoption.
- The market will benefit from strengthened regulatory frameworks supporting personalized medicine and growing partnerships between Chinese institutions and global pharmaceutical companies seeking efficient preclinical development solutions..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Merck KGaA
- Thermo Fisher Scientific Inc.
- SANOFI
- NOVARTIS
- Pfizer Inc.
Key Takeaways
- China's PDX models market is valued at $19.9 million in 2025 and is forecast to grow to $34.2 million by 2030, representing an 11.4% CAGR.
- China is emerging as a critical preclinical research hub, with increasing adoption of PDX models by pharmaceutical companies and research institutions.
- Government support for biotechnology innovation and precision medicine in China is driving investment in advanced tumor modeling platforms.
- China's expanding cancer research infrastructure and international collaborations are accelerating demand for patient-derived xenograft solutions through 2030.
Patient Derived Xenografts/PDX Models Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | ORTHOTOPIC IMPLANTATION (Implantation Method) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 12.5% from 2025 to 2030 |
| Largest Segment | PDX MODELS (Model Type & Service) |
| Market Size Base Year (Billions) | ~USD 0.37 (2025) |
| Revenue Forecast (Billions) | ~USD 0.66 (2030) |
| Segments Covered | Model Type & Service, Type, Implantation Method |
China Patient Derived Xenografts/PDX Models Market Report Segmentation
3 segment dimensions are covered across the global market.
By Model Type & Service
- Pdx Models
- Pdx Services
By Type
- Cryopreservation Services
- Model Characterization Services
- Model Creation & Expansion Services
- Mouse Model
- Other Pdx Services
- Rat Model
By Implantation Method
- Orthotopic Implantation
- Other Implantation Methods
- Subcutaneous Implantation
CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 4.94 | 5.51 | 6.15 | 6.87 | 7.64 | 8.46 | 9.37 | 10.36 | 11 |
| CROS & CDMOS | 3.24 | 3.59 | 4 | 4.45 | 4.93 | 5.44 | 5.99 | 6.6 | 10.5 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 10.4 | 11.68 | 13.15 | 14.83 | 16.62 | 18.57 | 20.74 | 23.13 | 11.9 |
| TOTAL | 18.58 | 20.78 | 23.3 | 26.15 | 29.19 | 32.47 | 36.1 | 40.08 | 11.5 |
Target Audience
- Pharmaceutical Companies : Need China-specific PDX market data to evaluate preclinical outsourcing opportunities, assess CRO capabilities, and plan drug development strategies in the world's fastest-growing pharma market.
- Biotech & CRO Firms : Require detailed market insights to benchmark PDX service offerings, identify competitive positioning, and develop growth strategies within China's expanding precision oncology research sector.
- Healthcare Investors & PE Firms : Need validated market sizing and growth projections for China to evaluate investment opportunities in PDX technology platforms, CROs, and precision medicine companies operating in the region.
- Academic & Research Institutions : Seek market intelligence on PDX adoption trends, funding opportunities, and collaboration potential with Chinese research centers to advance cancer research and personalized medicine initiatives.
- Medical Device & Diagnostics Companies : Require China market data to understand PDX integration opportunities, identify complementary technology partnerships, and develop companion diagnostic solutions for precision oncology applications.
Key Companies in the China Patient Derived Xenografts/PDX Models Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CHARLES RIVER LABORATORIES | United States | Public Company | Research Models and Services,Discovery and Safety Assessment,Manufacturing Solutions, |
| THE JACKSON LABORATORY | United States | Foundation/Charitable Institution | Mouse breeding & colony management,Phenotyping, efficacy testing & study-ready induced models,Genetic research services & bioinformatics, |
| INOTIV | United States | Public Company | Research Models and Services (RMS),Discovery and Safety Assessment (DSA) Services,BASi Scientific Instruments and Software, |
| JSR CORPORATION | Japan | Private Company | Digital Solutions (lithography, photoresists, CMP, display, 3D printing),Plastics (ABS, AES, AS, ASA resins),Life Sciences (diagnostics, reagents, bioprocess, drug discovery support), |
| GENOWAY | France | Public Company | Custom mouse models (KO/KI, humanized, immune checkpoint),Custom rat models (KO/KI, immunodeficient, reconstituted),Custom cell lines (KO/KI, reporter, inducible), |
| BIOCYTOGEN PHARMACEUTICALS CO., LTD. | China | Public Company | Gene-Editing Services,Pharmacological Efficacy and Toxicology Services,Model Animals, |
| CHAMPIONS ONCOLOGY, INC. | United States | Public Company | Tumorgraft-based translational oncology services,Personalized cancer care / patient-specific Tumorgraft programs,Lumin Bioinformatics and data-driven software, |
| PHARMARON | China | Public Company | Laboratory Services,Chemical and Formulation Process Development and Manufacturing Services (Small Molecule CDMO),Clinical Research Services, |
| SYNGENE INTERNATIONAL LIMITED | India | Public Company | Discovery services (chemistry and biology),Development services (preclinical, CMC, clinical development),Manufacturing (API and drug product, including biologics), |
| LABCORP | United States | Public Company | Routine and preventive diagnostics (chemistry, hematology, urinalysis, wellness),Specialty and esoteric testing (genetic, oncology, infectious disease, women’s health),Biopharma laboratory services and clinical trial testing, |
| EUROFINS SCIENTIFIC | Luxembourg | Public Company | Food and Feed Testing,Environmental Testing,Biopharma Testing and Services, |
CHARLES RIVER LABORATORIES
Charles River Laboratories is a public company founded in 1947 and headquartered in the United States. With 19,000 employees, it operates as a major provider of preclinical and clinical laboratory services.
THE JACKSON LABORATORY
The Jackson Laboratory is a foundation-based charitable institution founded in 1929 in the United States. The organization employs 2,100 staff members and focuses on genetic research and related scientific services.
INOTIV
INOTIV is a public company founded in 1974 and based in the United States. The company operates with 1,996 employees and provides research and development services.
JSR CORPORATION
JSR Corporation is a private company founded in 1948 and headquartered in Japan. With 7,997 employees, the company operates across multiple business segments.
GENOWAY
GENOWAY is a public company founded in 1999 and based in France. The organization employs 157 staff members and operates in the biotechnology sector.
BIOCYTOGEN PHARMACEUTICALS CO., LTD.
BIOCYTOGEN PHARMACEUTICALS CO., LTD. is a public company founded in 2008 and based in China. The company employs 1,443 staff members and operates in the pharmaceutical and biotechnology sectors.
CHAMPIONS ONCOLOGY, INC.
Champions Oncology, Inc. is a public company founded in 1985 and based in the United States. The company employs 214 staff members and operates in the oncology research and services sector.
PHARMARON
PHARMARON is a public company founded in 2004 and based in China. With 25,088 employees, the company provides drug discovery and development services.
SYNGENE INTERNATIONAL LIMITED
Syngene International Limited is a public company founded in 1993 and headquartered in India. The organization employs 6,692 staff members and provides integrated drug discovery and development services.
LABCORP
LabCorp is a public company founded in 1995 and based in the United States. With 66,385 employees, it operates as a major provider of clinical laboratory and diagnostic services.
EUROFINS SCIENTIFIC
Eurofins Scientific is a public company founded in 1987 and headquartered in Luxembourg. The organization employs 65,694 staff members and provides laboratory testing and analytical services across multiple industries.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise market valuation ($19.9M in 2025) and verified CAGR (11.4%) specific to China, enabling accurate financial forecasting and investment decision-making for the region.
- Competitive Landscape Intelligence : Understand China's unique market dynamics, key players, and competitive positioning within the Asia-Pacific PDX sector to identify partnership and expansion opportunities.
- Government Policy & Regulatory Insights : Access detailed analysis of Chinese government initiatives, healthcare policies, and regulatory frameworks driving PDX adoption in precision oncology and personalized medicine.
- Strategic Market Entry Planning : Leverage China-specific data to develop targeted market entry strategies, identify high-growth segments, and optimize resource allocation for pharmaceutical and biotech companies.
- Investment & Partnership Opportunities : Identify emerging CROs, academic institutions, and biotech firms in China with PDX capabilities, enabling strategic partnerships and investment decisions in the growing precision medicine ecosystem.
Frequently asked questions
What is the current market size of PDX models in China?
China's Patient Derived Xenografts market was valued at $19.9 million in 2025 and is expected to grow to $34.2 million by 2030.
What is the projected growth rate for China's PDX models market?
China's PDX models market is projected to grow at a compound annual growth rate (CAGR) of 11.4% from 2025 to 2030.
Which sectors are driving PDX adoption in China?
China's PDX market is driven by pharmaceutical companies, contract research organizations, academic institutions, and biopharmaceutical firms investing in precision oncology research.
How is China's government supporting the PDX models market?
China's government is supporting PDX market growth through biotechnology innovation initiatives, precision medicine programs, and regulatory reforms that encourage translational research.
What role do international collaborations play in China's PDX market?
International collaborations between Chinese research institutions and global pharmaceutical companies are accelerating PDX adoption and advancing China's preclinical research capabilities.
RESEARCH METHODOLOGY
This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global PDX model market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.
Secondary Research
Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the PDX model market. The secondary sources used for this study include World Health Organization (WHO), American Association for Cancer Research, American Association for Laboratory Animal Science, EurOPDX, European Animal Research Association, European Society for Medical Oncology, European Association for Cancer Research, Federation for Laboratory of Cell Therapy, International Journal of Non-Communicable Diseases, European Medicines Agency (EMA), Alliance for Regenerative Medicine (ARM); ACS Journals; Corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.
Secondary data were collected and analyzed to determine the overall size of the global PDX model market, which was subsequently validated through primary research. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate & validate the total size of the PDX model market. These methods were also used extensively to estimate the size of various market segments.
Data Triangulation
After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.
Market Definition
Patient-derived xenografts (PDXs) are models of cancer where the tissue or cells from a patient’s tumor are implanted into an immunodeficient or humanized mouse. These models have been used to grow cancer tissues after they were removed from a patient. The PDX model is an important tool for cancer research. It is used to study the biology of cancer, test the efficacy of new therapies, and predict the response to therapy in individual patients.
The study offers an in-depth analysis of the PDX model market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key PDX model product providers.
Stakeholders
- Pharmaceutical & biotechnology companies
- Contract research organizations (CROs)
- Academic & research institutes
- Preclinical and translational research centers
- Life science companies
- Regulatory bodies
- Contract development and manufacturing organizations (CDMOs)
- Cancer research consortia & foundations
- Venture capitalists & strategic investors
- Government associations
- Medical institutions & universities
- Hospitals & clinics
Report Objectives
- To define, describe, and forecast the PDX model market based on implantation method, type, tumor type, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall PDX model market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the PDX model market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as acquisitions, expansions, agreements, partnerships, and collaborations in the PDX model market
- To benchmark players within the PDX model market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy
Get the Full Patient Derived Xenografts/PDX Models Market Report
Full forecast, segment splits, and company analysis for all Patient Derived Xenografts/PDX Models Market.
- Canada Patient Derived Xenografts/PDX Models Market
- US Patient Derived Xenografts/PDX Models Market
- Germany Patient Derived Xenografts/PDX Models Market
- UK Patient Derived Xenografts/PDX Models Market
- France Patient Derived Xenografts/PDX Models Market
- Italy Patient Derived Xenografts/PDX Models Market
- Spain Patient Derived Xenografts/PDX Models Market
- Japan Patient Derived Xenografts/PDX Models Market
- India Patient Derived Xenografts/PDX Models Market
- Australia Patient Derived Xenografts/PDX Models Market
- South Korea Patient Derived Xenografts/PDX Models Market
- Brazil Patient Derived Xenografts/PDX Models Market
- Mexico Patient Derived Xenografts/PDX Models Market
- UAE Patient Derived Xenografts/PDX Models Market
- Rest Of Europe Patient Derived Xenografts/PDX Models Market
- Rest Of Asia Pacific Patient Derived Xenografts/PDX Models Market
- Rest Of Latin America Patient Derived Xenografts/PDX Models Market
- Kingdom Of Saudi Arabia Patient Derived Xenografts/PDX Models Market
- Rest Of GCC Countries Patient Derived Xenografts/PDX Models Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report